Jacobson & Schmitt Advisors LLC Takes $377,000 Position in AbbVie Inc. $ABBV

Jacobson & Schmitt Advisors LLC acquired a new stake in shares of AbbVie Inc. (NYSE:ABBV) during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 2,031 shares of the company’s stock, valued at approximately $377,000.

Several other large investors also recently added to or reduced their stakes in ABBV. Dillon & Associates Inc. lifted its position in shares of AbbVie by 3.3% in the second quarter. Dillon & Associates Inc. now owns 7,041 shares of the company’s stock worth $1,310,000 after buying an additional 227 shares during the last quarter. Sunburst Financial Group LLC lifted its holdings in AbbVie by 37.6% in the 2nd quarter. Sunburst Financial Group LLC now owns 2,223 shares of the company’s stock worth $413,000 after purchasing an additional 607 shares during the last quarter. Cassaday & Co Wealth Management LLC grew its holdings in AbbVie by 0.7% during the second quarter. Cassaday & Co Wealth Management LLC now owns 20,734 shares of the company’s stock valued at $3,849,000 after purchasing an additional 144 shares during the last quarter. Milestone Asset Management LLC raised its position in shares of AbbVie by 2.8% in the second quarter. Milestone Asset Management LLC now owns 8,507 shares of the company’s stock valued at $1,579,000 after purchasing an additional 234 shares during the period. Finally, NewSquare Capital LLC raised its position in shares of AbbVie by 58.6% in the second quarter. NewSquare Capital LLC now owns 1,726 shares of the company’s stock valued at $320,000 after purchasing an additional 638 shares during the period. 70.23% of the stock is owned by institutional investors.

Insider Activity

In other news, EVP Azita Saleki-Gerhardt sold 42,370 shares of the business’s stock in a transaction on Tuesday, August 12th. The shares were sold at an average price of $198.42, for a total value of $8,407,055.40. Following the sale, the executive vice president owned 177,292 shares in the company, valued at approximately $35,178,278.64. The trade was a 19.29% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.25% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on ABBV. DZ Bank lowered shares of AbbVie from a “buy” rating to a “hold” rating and set a $237.00 target price for the company. in a research report on Tuesday. JPMorgan Chase & Co. boosted their price objective on AbbVie from $250.00 to $260.00 and gave the stock an “overweight” rating in a research report on Monday. UBS Group set a $251.00 target price on AbbVie in a research note on Friday, October 3rd. Guggenheim lifted their price target on AbbVie from $227.00 to $242.00 and gave the stock a “buy” rating in a research report on Monday, October 20th. Finally, HSBC set a $225.00 price objective on AbbVie in a research report on Thursday, October 2nd. Two analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and ten have assigned a Hold rating to the stock. Based on data from MarketBeat.com, AbbVie currently has a consensus rating of “Moderate Buy” and a consensus price target of $237.81.

AbbVie Trading Up 1.9%

Shares of AbbVie stock opened at $216.09 on Wednesday. AbbVie Inc. has a 52-week low of $163.81 and a 52-week high of $244.81. The firm has a market capitalization of $381.73 billion, a PE ratio of 102.90, a price-to-earnings-growth ratio of 1.42 and a beta of 0.51. The company has a debt-to-equity ratio of 44.14, a current ratio of 0.74 and a quick ratio of 0.61. The company’s fifty day moving average price is $222.66 and its two-hundred day moving average price is $201.73.

AbbVie (NYSE:ABBV) last issued its earnings results on Friday, October 31st. The company reported $1.86 earnings per share for the quarter, beating the consensus estimate of $1.77 by $0.09. AbbVie had a net margin of 6.45% and a return on equity of 699.66%. The business had revenue of $15.78 billion for the quarter, compared to analyst estimates of $15.58 billion. During the same period in the previous year, the business earned $3.00 EPS. The firm’s revenue was up 9.1% on a year-over-year basis. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. On average, analysts expect that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 17th. Shareholders of record on Friday, January 16th will be paid a dividend of $1.73 per share. This is an increase from AbbVie’s previous quarterly dividend of $1.64. This represents a $6.92 annualized dividend and a yield of 3.2%. The ex-dividend date is Friday, January 16th. AbbVie’s dividend payout ratio is currently 524.24%.

AbbVie Company Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.